Smith & Nephew stock steady as Morgan Stanley and JPMorgan cut targets
Published on 09/02/2026 at 12:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Smith & Nephew stock (ISIN GB0009223206) is trading close to recent levels after fresh analyst downgrades, with London-listed shares closing at 10.63 GBP on the London Stock Exchange on September 1, 2026, and the Tradegate line at 12.60 USD-equivalent as of the same date according to data compiled from recent market overviews.
Analysts turn more cautious
According to an assessment reported by Investing.com on September 2, 2026, Morgan Stanley has downgraded Smith & Nephew from Overweight to Equalweight and reduced its price target from 13.04 GBP to 11.58 GBP, reflecting concerns about the company’s medium-term guidance.
The same report notes that another major bank lowered its recommendation from Overweight to Neutral and cut its price target from 14.38 GBP to 12.90 GBP, indicating that leading institutions now see more limited upside for the shares based on the latest outlook.
Q2 2026 results and growth profile
A recent earnings overview cited by a corporate-news summary updated on September 1, 2026 states that Smith & Nephew generated revenue of 1.6 billion USD in the second quarter of 2026, compared with analyst expectations of 1.64 billion USD for the same period.
The same summary indicates that underlying revenue in Q2 2026 increased by 1.6 percent year on year, while reported revenue rose by 2.8 percent versus the comparable quarter of 2025, highlighting that the top line is still growing but modestly relative to market forecasts.
Further information on Smith & Nephew stock
More articles, regulatory news and background information on Smith & Nephew stock can be found in the dedicated topic overview.
Product portfolio and orthopedic focus
Smith & Nephew is known for its orthopedics and sports medicine portfolio, including hip and knee replacement systems and related surgical tools, a segment that remains central to its revenue mix in 2026.
Stock performance and market view
According to the same corporate-news summary based on data up to September 1, 2026, Smith & Nephew’s London-listed shares closed at 10.63 GBP on the London Stock Exchange, while the Tradegate listing in the German market stood at 12.60 USD-equivalent, indicating that the stock is trading modestly below average analyst targets.
Smith & Nephew at a glance
- Company: Smith & Nephew plc
- ISIN: GB0009223206
- Ticker: SNN
- Trading venue: LSE/NYSE, Tradegate secondary listing
- Sector / Industry: Healthcare / Medical Devices
- Index membership: FTSE 100
